HCG Research Overview (also known as Human Chorionic Gonadotropin, hCG, Choriogonadotropin alfa)
Human Chorionic Gonadotropin — a glycoprotein hormone produced naturally during pregnancy that mimics Luteinizing Hormone (LH) at the LH receptor. In research contexts HCG is studied for stimulating testicular testosterone production, preserving gonadal function during exogenous androgen protocols, and fertility restoration.
What Is HCG?
Human Chorionic Gonadotropin (HCG) is a 237-amino-acid glycoprotein hormone naturally produced by syncytiotrophoblast cells of the placenta during pregnancy. Structurally related to LH, FSH, and TSH — all sharing an identical α-subunit and differing only in their β-subunits — HCG's similarity to LH allows it to bind and activate the LH/HCG receptor on Leydig cells in the testes with high affinity.
Primary Research Functions
HCG stimulates Leydig cells to produce testosterone, making it central to research on hypogonadism, testosterone replacement, and fertility support. Unlike exogenous testosterone, which suppresses the HPG axis and reduces endogenous LH signaling, HCG provides direct LH-like stimulation at the testicular level without pituitary suppression of downstream gonadotropins.
Gonadal Preservation Research
A prominent area of HCG research involves co-administration with testosterone therapy to maintain testicular size, function, and intratesticular testosterone concentrations — the latter being essential for spermatogenesis even when systemic testosterone levels are adequate. Studies show HCG effectively preserves sperm parameters and testicular volume during androgen protocols.
Female and Fertility Applications
In female fertility research, HCG serves as an LH surrogate that triggers ovulation during controlled ovarian stimulation cycles and as the ovulation-triggering agent in IVF protocols after follicle maturation.
Quick Reference
| Literature-Reported Dose Range | 500-1000 IU twice weekly for TRT adjunct |
| Literature-Reported Frequency | 2-3 times weekly |
| Literature-Reported Cycle Length | Ongoing during TRT; 3-6 months for fertility |
| Literature-Reported Washout | Not typically cycled when used as TRT adjunct |
| Storage | Refrigerate after reconstitution; use within 30-60 days |
| Sites Reported in Studies | SubQ: abdomen, thigh. IM: deltoid, gluteal |
| Timing | Consistent schedule more important than specific time |
Research Indications
Growth Hormone
Hypogonadotropic Hypogonadism
FDA-approved for secondary hypogonadism to stimulate testosterone production
Testosterone Support
Indirectly supports body composition by maintaining testosterone levels
Recovery
Fertility Preservation
Maintains spermatogenesis and testicular function during TRT
TRT Adjunct
Commonly used to maintain testicular function and fertility during testosterone replacement
Body Composition
Cryptorchidism Treatment
FDA-approved for undescended testes in prepubertal boys
Ovulation Induction
FDA-approved to trigger ovulation in assisted reproduction
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| TRT Adjunct | 250-1000 IU | 2-3x weekly | SubQ or IM |
| Monotherapy | 1500-2000 IU | 2-3x weekly | IM |
| Fertility Protocol | 1500-2000 IU + FSH | 2-3x weekly | IM |
Timing
Recommended administration window: consistent schedule more important than specific time. Typical onset: 1-2 weeks: testosterone increase; 2-4 weeks: testicular fullness; 2-3 months: fertility improvement.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
HCG is frequently used alongside TRT to maintain testicular function, preserve fertility, and prevent atrophy. Standard TRT protocol: 250-500 IU HCG twice weekly
Both stimulate testosterone production via different mechanisms. Sometimes used sequentially in PCT protocols. Generally not combined simultaneously - choose one approach
HCG increases intratesticular aromatase activity and may elevate estrogen. AIs like anastrozole are often used concurrently to manage estrogen levels during TRT+HCG protocols
GnRH agonists/antagonists suppress LH. HCG may be used to maintain testicular function during GnRH analog therapy or for recovery afterward. Timing coordination required
Combined HCG + FSH therapy is standard for male infertility treatment in hypogonadotropic hypogonadism, achieving spermatogenesis in 70-90% of patients
High-dose HCG has weak TSH-like activity due to alpha subunit homology. Can cause transient hyperthyroidism with very high HCG levels (pregnancy, tumors). Monitor thyroid function
In women with PCOS undergoing ovulation induction, metformin may reduce ovarian hyperstimulation syndrome risk when combined with HCG. Often used together in fertility protocols
Both elevate LH-like signaling — HCG provides direct LH-receptor stimulation while Enclomiphene raises endogenous LH via SERM action. Full doses of both simultaneously can cause excessive estrogen surge. If combining, reduce Enclomiphene to 6.25–12.5 mg and monitor estrogen closely.
HCG elevates testosterone and consequently estrogen. An aromatase inhibitor is a recommended companion in HCG protocols to manage estrogen elevation and prevent gynecomastia. This is a standard clinical pairing in male hormone optimization.
When used together, HCG preserves testicular function and prevents atrophy caused by exogenous testosterone suppressing LH. Standard pairing. However, the combined testosterone + HCG estrogen load requires monitoring — have an AI available and track estrogen every 6–8 weeks.
Reported Research Timeline
01Week 1–2 (reported in cited studies): testosterone levels begin rising
02Week 2–4 (reported in cited studies): testicular fullness improves; well-being improves
03Month 2–3 (reported in cited studies): fertility parameters improve with sustained use
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
May cause or worsen gynecomastia - monitor estrogen
Risk of OHSS in women - requires monitoring
Not Recommended in hormone-sensitive cancers
May cause fluid retention and headaches
Thromboembolism risk may be elevated
Seek Medical Attention If:
Severe abdominal pain (women - OHSS)
Leydig cell desensitization can occur with very high doses (>2,000 IU three times per week) used long-term. Paradoxically, excessive HCG can reduce testicular LH-receptor sensitivity over time. Keep doses at the minimum effective level — typically 500–1,000 IU twice weekly for TRT adjunct use.
Polycythemia (elevated red blood cell count and hematocrit) is a known risk with HCG, mediated through testosterone elevation. Monitor hematocrit every 3–6 months during ongoing use — particularly important for individuals already on TRT.
Women using HCG in fertility protocols are at risk of Ovarian Hyperstimulation Syndrome (OHSS) — a potentially serious condition causing ovarian swelling, fluid shifts, and in severe cases, blood clots. Any female use of HCG must be clinically supervised.
Quality Indicators
Verified Marker
White lyophilized powder
Proper powder appearance in sealed vial
Verified Marker
Clear solution after reconstitution
Must be completely clear with no particles
Quality Concern
Cloudy or discolored
Indicates degradation - do not use
Research Citations
- Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression
Coviello AD, Matsumoto AM, Bremner WJ, et al., 2005, J Clin Endocrinol Metab - Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy
Kohn TP, Louis MR, Pickett SM, et al., 2017, Fertil Steril - Management of endocrine disease: reversible hypogonadotropic hypogonadism
Dwyer AA, Raivio T, Pitteloud N, 2016, Eur J Endocrinol - Biological functions of hCG and hCG-related molecules
Cole LA, 2010, Reprod Biol Endocrinol - A short evolutionary history of FSH-stimulated spermatogenesis
Huhtaniemi I, 2018, Hormones (Athens) - HCG Diet Products Are Illegal
FDA, 2011, FDA Consumer Update - Exogenous testosterone: a preventable cause of male infertility
Crosnoe LE, Grober E, Ohl D, Kim ED, 2013, Transl Androl Urol - Recombinant versus urinary-derived hCG for ovulation induction
Hershlag A, Peterson CM, 2003, Fertil Steril
""
Research Focus
Testosterone production, Gonadal preservation, Fertility, Hypogonadism, Post-cycle recovery
Verified Vendors Carrying HCG
Frequently Asked Questions
What should researchers watch for with HCG?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with HCG?
Week 1–2 (reported in cited studies): testosterone levels begin rising
How is HCG typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →